PATHOPHYSIOLOGY HF/AHF Disease Awareness. HF=heart failure; LV=left ventricular 1. Alla et al. Heart Fail Rev 2007;12:91–5; 2. Gheorghiade et al. Am J.

Slides:



Advertisements
Similar presentations
HEART FAILURE (HF) Heart failure is the pathophysiological state in which an abnormality of cardiac function is responsible for failure of the heart to.
Advertisements

Evaluation and Management of Acute Decompensated Heart Failure
Lecture:10 Contractility, Stroke volume and Heart Failure
Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):
HEART FAILURE: ANSWERS YOU NEVER GET TO QUESTIONS YOU ALWAYS ASK BART COX, M.D.FACC DIRECTOR, ADVANCED HEART FAILURE PROGRAM ASSOCIATE PROFESSOR OF MEDICINE.
Perioperative Management of Heart Failure Gamal Fouad S Zaki, MD Professor of Anesthesiology Ain Shams University
Congestive Heart Failure
 Heart failure is a complex clinical syndrome Can result from:  structural or functional cardiac disorder  impairs the ability of the ventricle to.
Right Ventricular Failure (RVF) Occurs when the right ventricle fails as an effective forward pump, causing back-pressure of blood into the systemic.
UNMET NEED AHF/HF Disease Awareness. Morbidity and Mortality: Patients with heart failure are on a downward spiral, with frequent hospitalizations and.
Diastolic Heart Failure, HFpEF, HFnEF: What are we treating anyway? Charles M. Rasmussen, MD FACC.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
1 Cardiac Pathophysiology Part B. 2 Heart Failure The heart as a pump is insufficient to meet the metabolic requirements of tissues. Can be due to: –
Bio-Med 350 Normal Heart Function and Congestive Heart Failure.
Congestive Heart Failure Stephen Gottlieb, MD Professor of Medicine Director, Cardiomyopathy and Pulmonary Hypertension University of Maryland.
Heart Failure Whistle Stop Talks No 1 HFrEF and HFpEF Definitions for Diagnosis Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
Dr. Meg-angela Christi M. Amores
DIASTOLIC DYSFUNCTION AND HEART FAILURE PHYSIOLOGY, HISTORICAL FEATURES AND CLINICAL PERSPECTIVE Medicine Resident Rounds September 28, 2007 Jacobi Hospital.
Heart Failure Whistle Stop Talks No. 2 Classification Implications Susie Bowell BA Hons, RGN Heart Failure Specialist Nurse.
HEART FAILURE PROF. DR. MUHAMMAD AKBAR CHAUDHRY M.R.C.P.(U.K) F.R.C.P.(E) F.R.C.P.(LONDON) F.A.C.C. DESIGNED AT A.V. DEPTT F.J.M.C. BY RABIA KAZMI.
Ventricular Diastolic Filling and Function
Heart Failure John Lynn Jefferies, MD, MPH, FAAP, FACC Director, Cardiomyopathy, Advanced Heart Failure, and Ventricular Assist Device Programs Co-Director,
Heart Failure Khalid F AlHabib.MBBS.FRCPC Cardiology Consultant King Fahad Cardiac Centre King Saud University Wednesday, September 02, 2015Wednesday,
Heart Failure Ben Starnes MD FACC Interventional Cardiology
 By the end of this lecture the students are expected to:  Understand the concept of preload and afterload.  Determine factors affecting the end-diastolic.
INTRODUCTION TO HEART FAILURE
The Relationship Between Renal Function and Cardiac Structure, Function, and Prognosis Following Myocardial Infarction: The VALIANT Echo Study Anil Verma,
The burden Of heart failure
Chronic Heart Failure – An Update T P Chua Royal Surrey County Hospital, Guildford St George’s Hospital, London.
Frank-Starling Mechanism
Nursing and heart failure
Heart Failure Claire B. Hunter, MD. Heart Failure is the inability of the heart to pump sufficient blood to the body tissue to meet ordinary metabolic.
Aortic Insufficiency Acute and Chronic
To know more visit HeartFailure.com
Myocardial Infarction  MI = heart attack  Defined as necrosis of heart muscle resulting from ischemia.  A very significant cause of death worldwide.
Acute Heart Failure in Apical Ballooning Syndrome (Takotsubo/Stress Cardiomyopathy) Clinical Correlates and Mayo Clinic Risk Score Malini Madhavan, MBBS;
Systolic Versus Diastolic Failure. Forms of Heart Failure Sytolic Failure Inability of the ventricle to contract normally and expel sufficient blood Inadequate.
Haissam A Haddad, MD, FRCPC, FACC University of Ottawa Heart Institute
Heart failure Laszlo L. Tornoci Inst. Pathophysiology Semmelweis University.
Internal Medicine Workshop Series Laos September /October 2009
Exercise Management Chronic Heart Failure Chapter 12.
 By the end of this lecture the students are expected to:  Explain how cardiac contractility affect stroke volume.  Calculate CO using Fick’s principle.
Myocardial Infarction
NTproBNP for the Exclusion of Heart Failure Richard Blakey.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.
Date of download: 6/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effect of Serelaxin on Cardiac, Renal, and Hepatic.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.
Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease Angela Y-M Wang, Mei Wang, Christopher W-K Lam,
Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.
신장내과 R4 강혜란 Cardiorenal syndrome (CRS).  Patients with heart failure (HF) who have a reduced GFR -> Mortality ↑  Patients with chronic kidney disease.
Clinical Outcomes with Newer Antihyperglycemic Agents
Heart failure has two distinctive subtypes
  Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.
Chronic heart failure By Vishal Patel GPVTS1.
Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, Marvin A. Konstam, G. Michael.
Clinical Outcomes with Newer Antihyperglycemic Agents
HYPERTENSIVE HEART DISEASE (Hypertensive cardiomyopathy)
Pharmacotherapy Of Cardiovascular Disorders: Heart Failure
Heart Failure NURS 241 Chapter 35 (p.797).
Effect of Phosphodiesterase-5 Inhibition on Exercise
Copyright © 2015 by the American Osteopathic Association.
Emergency Nursing Assessment Cardiac Exam
Heart Rate, Life Expectancy and the Cardiovascular System: Therapeutic Considerations Cardiology 2015;132: DOI: / Fig. 1. Semilogarithmic.
Left Ventricular Dysfunction With Pulmonary Hypertension
Heart Failure Prognosis & Management
The pathophysiology of myocardial infarction-induced heart failure
Done by: Tamador A. Zetoun
Division of Cardiovascular Diseases No relevant author disclosures
Khalid AlHabib Professor of Cardiac Sciences Cardiology Consultant
Patrick O’Gara et al. JIMG 2008;1:
Presentation transcript:

PATHOPHYSIOLOGY HF/AHF Disease Awareness

HF=heart failure; LV=left ventricular 1. Alla et al. Heart Fail Rev 2007;12:91–5; 2. Gheorghiade et al. Am J Cardiol 2005;96:11G–17G The pathophysiology of heart failure results in an increasingly downward spiral Acute decompensated HF is associated with frequent hospitalizations 1 With each hospitalization, there is likely myocardial and renal damage that contributes to progressive LV or renal dysfunction, leading to an inevitable downward spiral 2 Cardiac function and quality of life Hospitalizations Time Chronic HF Acute decompensation Cardiac and renal damage/ incomplete recovery More rapid decline in chronic HF Increased risk of decompensations

Clinical classification of acute heart failure reflects a spectrum of overlapping presentations ACS=acute coronary syndrome; AHF=acute HF; HF=heart failure; JVP=jugular venous pressure; LV=left ventricular; MI=myocardial infarction; SBP=systolic blood pressure 1. Gheorghiade et al. Circulation 2005;112:3958–68; 2. Dickstein et al. Eur Heart J 2008;29:2388–442 Hypertensive AHF Cardiogenic shock ACS and HF Pulmonary edema Right HF Acutely decompensated chronic HF 70% incidence 1 Usually a history of progressive worsening of chronic HF on treatment and evidence of systemic and pulmonary congestion 2 Unknown incidence 1 Low output syndrome in the absence of pulmonary congestion, increased JVP and low LV filling pressures 2 >50% incidence for ↑ SBP 1 Mainly pulmonary rather than systemic congestion 1 Many patients have preserved ejection fraction 1 <3% incidence 1 Clinical characteristics: severe dyspnea, tachypnea, tachycardia and hypoxemia, which may require immediate airway intervention 1 Unknown incidence 1 Many patients have signs and symptoms of ACS that resolve after initial therapy or resolution of ischemia 1 Acute HF frequently precipitated by or associated with an arrhythmia 2 <1% incidence 1 Primarily complicating acute MI, fulminant myocarditis 1 Tissue hypoperfusion after adequate correction of preload and major arrhythmia 2

The Short-term and long-term Pathophysiogical consequences of AHF ‡ NT-pr Preload Afterload Congestion NT- proBNP Vaso- constriction Decreased cardiac function Fluid overload Myocardial overload and renal dysfunction Organ damage and dysfunction Hemodynamic abnormalities Neurohormonal activation Oxidative stress Inflammation O 2 supply-demand mismatch ‡Proposed schematic of acute heart failure pathophysiology Biolo et al. Circ Heart Fail 2010;3:44–50; Bott-Flügel et al. Eur J Heart Fail 2008;10:129–32; Cotter et al. Am Heart J 2008;155:9–18; Cotter et al. Eur J Heart Fail 2008;10:165–69; Feng & Wang. J Geriatr Cardiol 2008;5:1–6; Hunt et al. J Am Coll Cardiol 2009;53:e1–e90; Oikonomou et al. Hellenic J Cardiol 2011;52:30–40; Tsutsui et al. Am J Physiol Heart Circ Physiol 2011;301:H2181–90 Processes mediating long-term effects Amplification phase Processes mediating short-term effects Initiation phase Renal dysfunction as shown by ↑ Cystatin C, ↑ Creatinine, ↑ BUN Renal damage as shown by ↑ uric acid Myocardial fibrosis and remodelling as shown by ↑ fibroblast proliferation and activation Myocardial damage as shown by ↑ hs-cTnT

Patterns of ventricular remodelling are different for HFrEF and HFpEF HFpEF=heart failure with preserved ejection fraction; HFrEF=heart failure with reduced ejection fraction Adapted from Colucci (Ed.). Atlas of Heart Failure, 5th ed. Springer 2008; Grossman et al. In: Perspectives in Cardiovascular Research; Myocardial Hypertrophy and Failure. Vol 7. Edited by Alpert NR. New York: Raven Press;1993:1–15 Increased systolic pressure Increased systolic wall stress Parallel addition of new myofibrils Wall thickening Concentric hypertrophy Pressure overload Volume overload Increased diastolic pressure Increased systolic wall stress Series addition of new sarcomeres Chamber enlargement Eccentric hypertrophy HFpEFHFrEF HFpEF – a condition of pressure overload characterized by concentric hypertrophic growth results in normal sized LV cavity with thickened walls and preserved systolic function Left ventricle normal Left ventricle pressure overload Left ventricle volume overload HFrEF – a condition of volume overload characterized by eccentric hypertrophy results in globular heart with thinning of the LV walls, decreased systolic function and enlarged left ventricular volume

Long-term Consequences of AHF: Higher NT- proBNP levels are associated with increased risk of mortality in patients with AHF NT-proBNP levels increase Quartile of NT-proBNP Hazard Ratio95% CI p value 1 st 1.0Reference 2 nd – rd – th –9.9<0.001 Hazard ratio AHF=acute heart failure; CI=confidence interval; NT-proBNP=N-terminal-pro-B-type natriuretic peptide ‡Analysis of data from 568 patients hospitalized for AHF in the Biomarkers in Acute Heart Failure (BACH) study †The NT-proBNP cutoffs were 2,248, 5,017, and 10,455 pg/mL for the 25th, 50th and 75th percentiles, respectively 1. Biolo et al. Circ Heart Fail 2010;3:44–50; 2. Maisel et al. J Am Coll Cardiol 2010;55:2062–76 Higher levels of NT-proBNP are associated with increased risk of mortality by 90 days in patients hospitalized for AHF ‡2 During episodes of AHF 1

Long-term Consequences of AHF: Cardiac troponin, a marker of myocyte injury/death, is commonly elevated in AHF and is associated with increased mortality Elevated troponin is associated with poor outcomes in AHF 1 Troponin is often released in patients with AHF 1 Cardiac troponin T (g/L) AHF=acute heart failure ‡Analysis of data from 364 patients hospitalized for AHF from the Finnish Acute Heart Failure (FINN-AKVA) study 1. Kociol et al. J Am Coll Cardiol 2010;56:1071–8; 2. Ilva et al. Eur J Heart Fail 2008;10:772–9 Higher levels of troponin T predict greater mortality in patients with AHF ‡2 All-cause mortality at 6 months (%) P=0.002 P=0.007

Long-term Consequences of AHF: Worsening renal function in patients hospitalized for AHF predicts poor outcomes >0.5 mg/L increase in cystatin C ≤0.5 mg/L increase in cystatin C Maggioni et al. Eur J Heart Fail 2010;12:1076–84; 2. Rudiger et al. Eur J Heart Fail 2005;7:662–70; 3. Forman et al. J Am Coll Cardiol 2004;43:61–7; 4. Akhter et al. Am J Cardiol 2004;94:957–60; 5. Lassus et al. Eur Heart J 2010;31:2791–98 AHF=acute heart failure †Renal impairment defined as an estimated glomerular filtration rate <50 mL/min/1.73 m2 or creatinine clearance <50 mL/min; #Worsening of renal function defined as an increase in serum creatinine of >0.3 mg/dL or >0.5 mg/dL; ‡Analysis of data from 292 patients hospitalized for AHF from the Finnish Acute Heart Failure (FINN-AKVA) study Further worsening of renal function occurs in ~25% of patients hospitalized for AHF #3,4 ~30–40% of patients hospitalized for AHF have renal impairment †1,2 An increase in cystatin C in the first 48 hours following hospitalization for AHF is associated with poor prognosis ‡ Days Cumulative mortality Item Code: Copyright © Novartis Pharma AG.